BridgeBio Shares Rise After Positive Phase 3 Results for Oral Infigratinib in Achondroplasia
BridgeBio Pharma reported positive topline results from its Phase 3 PROPEL 3 trial of oral infigratinib in achondroplasia, driving a 9% intraday gain in the company’s stock. The study met its primary endpoint for annualized height velocity at Week 52 and showed a statistically significant improvement in body proportionality in a pre-specified subgr…